Induction of Bordetella pertussis-specific immune memory by DTPa vaccines. (Q51017705)

27 March 2018

title

Induction of Bordetella pertussis-specific immune memory by DTPa vaccines. (English)

1 reference

27 March 2018

1 reference

Sandra Morel

1

1 reference

27 March 2018

Philippe Denoël

2

1 reference

27 March 2018

Fabrice Godfroid

3

1 reference

27 March 2018

Caroline Cortvrindt

4

1 reference

27 March 2018

Nathalie Vanderheyde

5

1 reference

27 March 2018

Jan Poolman

6

1 reference

27 March 2018

language of work or name

English

0 references

publication date

5 March 2011

1 reference

27 March 2018

published in

Vaccine

1 reference

27 March 2018

volume

29

1 reference

27 March 2018

issue

18

1 reference

27 March 2018

page(s)

3449-3455

1 reference

27 March 2018

Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Systematic review of the effects of pertussis vaccines in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

How to make sense of pertussis immunogenicity data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Acellular pertussis vaccines and the role of pertactin and fimbriae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Stage II Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Duration of immunity against pertussis after natural infection or vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Long-term presence of memory B-cells specific for different vaccine components.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Clonal dissection of the human memory B-cell repertoire following infection and vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Duration of humoral immunity to common viral and vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Distinction of the memory B cell response to cognate antigen versus bystander inflammatory signals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Maintenance of serological memory by polyclonal activation of human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Diphtheria-tetanus-pertussis (DTP) combination vaccines and evaluation of pertussis immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

A search for Bordetella pertussis infection in university students

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Health burden of pertussis in adolescents and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Transmission of Bordetella pertussis to young infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

New Pertussis Vaccination Strategies beyond Infancy: Recommendations by the Global Pertussis Initiative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Safety and immunogenicity of an acellular pertussis diphtheria tetanus vaccine given as a single injection with Haemophilus influenzae b conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Modulation of the infant immune responses by the first pertussis vaccine administrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Ad hoc Working Group on acellular pertussis vaccines, World Health Organisation, Geneva, 27-28 July 2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

WHO Working Group on the standardisation and control of pertussis vaccines-report of a meeting held on 6-7 May 2003, Ferney Voltaire, France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.062

10.1016/J.VACCINE.2011.02.062

7 January 2021

Identifiers

DOI

1 reference

27 March 2018

1 reference

27 March 2018